The initial dose of SEMINTRA (telmisartan oral solution) is 1.5 mg/kg (0.68 mg/lb) orally twice daily for 14 days, followed by 2 mg/kg (0.91 mg/lb) orally once daily. The dose may be reduced by 0.5 mg/kg (0.23 mg/lb) increments to a minimum of 0.5 mg/kg (0.23 mg/lb) orally once daily to manage SEMINTRA-induced hypotension. SEMINTRA can be administered directly into the mouth, or next to or on top of a small amount of food. Do not mix into food. SEMINTRA should be administered using the dosing syringe provided in the package. The dosing syringe fits onto the bottle and has 0.1 mL incremental marks. The dose should be rounded to the nearest 0.1 mL. After administration close the bottle tightly with the cap. Rinse the dosing syringe with water and let air dry. If the cat vomits within 30 minutes of dosing, the cat may be re-dosed.

SEMINTRA (telmisartan oral solution) has not been evaluated in cats with systolic blood pressure >200 mm Hg. SEMINTRA can cause mild anemia or nonregenerative anemia. Cats should be monitored for anemia when initiating treatment with SEMINTRA. SEMINTRA may cause inappetence and weight loss in some cats. Cats should be monitored for weight loss when initiating treatment with SEMINTRA. Use with caution in cats with a history of vomiting, inappetence or weight loss. The safe use of SEMINTRA in cats with hepatic disease has not been evaluated. SEMINTRA is metabolized by the liver. The safe use of SEMINTRA has not been evaluated in cats less than 9 months of age. The safe use of SEMINTRA has not been evaluated in cats that are pregnant, lactating, or intended for breeding. See Human Warnings under the IMPORTANT SAFETY INFORMATION. The safe use with other anti-hypertensive medications has not been evaluated.